BRUSSELS (Thomson Financial) - Belgian drug developer OncoMethylome Sciences SA said it has signed a broad technology licensing agreement with German peer Epigenomics AG, giving OncoMethylome worldwide nonexclusive rights to several of Epigenomics' proprietary core technologies.
